Cardarine (GW-501516)

Research-Backed Insights Into Metabolic Performance and Endurance

Introduction and Overview

Cardarine, scientifically known as GW-501516 (also referenced as GW1516 or Endurobol), is a synthetic compound originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s for metabolic and cardiovascular research. While it is often grouped with selective androgen receptor modulators (SARMs), Cardarine is not a SARM. Instead, it functions through a completely different biological pathway—activation of PPAR-δ (peroxisome proliferator- activated receptor delta), a nuclear receptor involved in energy metabolism, lipid utilization, and mitochondrial function. PPAR-δ receptors are highly expressed in tissues with high metabolic demand, including skeletal muscle, liver, cardiac tissue, and the brain. When activated, these receptors regulate gene expression related to fatty acid transport and oxidation, mitochondrial biogenesis, glucose sparing during prolonged activity, and cellular energy efficiency. Because of this unique mechanism, Cardarine has drawn significant interest in research settings focused on endurance, metabolic efficiency, and lipid regulation. Preclinical studies revealed that Cardarine could actively accelerate metabolism, reduce adiposity, increase fatty acid beta-oxidation in muscle, and improve physical performance in animal models. However, high-dose, long-term rodent studies raised safety concerns including increased cancer risk in certain tissues, which halted pharmaceutical development. Despite this, GW-501516 remains one of the most extensively studied PPAR-δ agonists in metabolic and endurance research. GW-501516 is not FDA-approved for any indication, is not intended for human consumption, and is prohibited by the World Anti-Doping Agency (WADA) under the S4.5 Metabolic Modulators category. It is available strictly as a research compound.

Quick Reference

Property Detail Chemical Name 2-[2-Methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3- thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Code Names GW-501516, GW1516, Endurobol Drug Class PPAR-δ (peroxisome proliferator-activated receptor delta) agonist Molecular Formula C₂₁H₁₈F₃NO₃S₂ Molecular Weight 453.5 g/mol CAS Number 317318-70-0 Route Oral (capsule or liquid) Primary Target PPAR-δ nuclear receptor Developer GlaxoSmithKline / Ligand Pharmaceuticals (1990s) Development Status Discontinued (safety concerns in rodents); research chemical only WADA Status Prohibited at all times (S4.5 Metabolic Modulators, since 2009)

How It Works

PPAR-δ Receptor Activation

GW-501516 binds selectively to PPAR-δ with high affinity, triggering transcriptional changes that shift energy metabolism toward fat utilization over glucose. PPAR-δ is a nuclear receptor that functions as a ligand-dependent transcription factor, binding to consensus response elements on chromatin in a heterodimer with the retinoid X receptor (RXR). When activated by GW- 501516, PPAR-δ upregulates a coordinated program of genes involved in fatty acid transport, beta-oxidation, mitochondrial biogenesis, and energy uncoupling. This mechanism was demonstrated in the landmark study by Dressel et al. (2003), which showed that GW-501516 treatment of skeletal muscle cells induced the expression of genes involved in lipid catabolism, cholesterol efflux, and energy uncoupling. The resulting metabolic shift reduces reliance on glycogen stores and increases the proportion of energy derived from fatty acid oxidation—a pattern that closely mimics the metabolic adaptations of endurance training.

Fatty Acid Oxidation and Metabolic Shift

The core metabolic effect of GW-501516 is enhanced fatty acid oxidation (FAO). Activation of PPAR-δ increases the expression of carnitine palmitoyltransferase-1 (CPT-1), the rate-limiting enzyme for fatty acid transport into mitochondria, as well as PGC-1α (peroxisome proliferator- activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis. This upregulates the entire fatty acid oxidation pathway, shifting the body’s fuel preference from glucose to lipids. Brunmair et al. (2006) confirmed this mechanism in isolated rat skeletal muscle, demonstrating that PPAR-δ activation directly switches fuel preference from glucose to fatty acids at the cellular level.

Mitochondrial Biogenesis

GW-501516 stimulates mitochondrial biogenesis—the creation of new mitochondria within cells. This increases the oxidative capacity of skeletal muscle, allowing for greater energy production from fatty acid oxidation. Increased mitochondrial density is a hallmark adaptation of endurance training, and GW-501516 induces this adaptation pharmacologically. The compound also increases the proportion of succinate dehydrogenase (SDH)-positive muscle fibers (type I, slow-twitch oxidative fibers), further enhancing endurance capacity.

Muscle Fiber-Type Reprogramming

Research by Wang et al. (2004) demonstrated that PPAR-δ overexpression in skeletal muscle reprograms muscle fiber types toward a more oxidative phenotype. Transgenic mice with constitutively active PPAR-δ showed increased type I (slow-twitch) fibers, which are more resistant to fatigue and rely more heavily on fatty acid oxidation. GW-501516 pharmacologically induces similar fiber-type shifts, contributing to its endurance-enhancing effects.

Anti-Inflammatory Signaling

PPAR-δ plays a role in regulating inflammatory gene expression. Activation has been associated with reductions in inflammatory markers in multiple experimental models, particularly those involving metabolic dysfunction. This anti-inflammatory effect may contribute to improved recovery and reduced exercise-induced inflammation, and is relevant to the compound’s potential applications in cardiometabolic disease research.

Benefits

Enhanced Fatty Acid Oxidation

Preclinical and early clinical research demonstrates that PPAR-δ activation significantly increases the body’s ability to oxidize fatty acids for energy. This metabolic shift is associated with improved endurance capacity and reduced reliance on glycogen stores. The first human trial (Sprecher et al., 2007) confirmed that GW-501516 significantly influenced HDL cholesterol and triglyceride levels in healthy volunteers, with enhanced in vivo serum fat clearance.

Improved Endurance and Work Capacity

Animal models consistently demonstrate increased running time and resistance to fatigue following PPAR-δ activation. The landmark Narkar et al. (2008) study published in Cell showed that GW-501516 enabled mice to run 60% to 75% longer and further than controls. When combined with exercise training, the effect was synergistic—greater than either drug or exercise alone. These effects stem from improved mitochondrial efficiency, fiber-type remodeling, and preservation of glucose for critical tissues.

Favorable Lipid Profile Modulation

Studies in animal models, primates, and healthy human volunteers demonstrate that GW-501516 increases HDL (“good”) cholesterol while reducing triglycerides and VLDL levels:

• Sprecher et al. (2007): First human trial; 2 weeks of GW-501516 (2.5 mg and 10 mg)

significantly increased HDL, decreased triglycerides, reduced LDL, and improved triglyceride clearance after fat feeding in healthy sedentary volunteers.

• Ooi et al. (2011): GW-501516 produced significant changes in HDL cholesterol, LDL

cholesterol, apoA1, and apoB in subjects with low HDL and metabolic syndrome characteristics. Fewer VLDL particles and larger LDL particles supported a transition toward less atherogenic lipoprotein profiles.

• Olson et al. (2012): GW-501516 reversed multiple metabolic abnormalities associated

with metabolic syndrome in moderately obese men without increasing oxidative stress, likely through enhanced fat oxidation in skeletal muscle.

Insulin Sensitivity and Glucose Regulation

By enhancing fatty acid utilization and mitochondrial signaling, PPAR-δ agonists have been shown to improve insulin sensitivity and glucose tolerance in metabolic research models. GW- 501516 ameliorated insulin resistance and improved dyslipidemia in metabolic syndrome mouse models (Chen et al., 2008). However, some studies suggest the glucose effects may be secondary to improved lipid metabolism rather than a direct effect on insulin signaling.

Anti-Inflammatory Effects

PPAR-δ activation has been associated with reductions in inflammatory markers in multiple experimental models, particularly those involving metabolic dysfunction. Paw et al. (2023) demonstrated that GW-501516 suppresses the TGF-β-induced profibrotic response in human bronchial fibroblasts, suggesting potential anti-inflammatory applications beyond metabolic disease.

What the Science Shows

Study 1: Narkar et al. – Cell (2008) Design: Preclinical study at the Salk Institute testing the effects of GW-501516 (referred to as GW1516) on exercise endurance in mice, using treadmill running tests. Mice received GW- 501516 alone, exercise training alone, or the combination. The study also tested the AMPK agonist AICAR to determine whether the exercise requirement could be overcome pharmacologically. Results: GW-501516 and exercise training synergistically increased oxidative myofibers and running endurance. GW-501516 alone enabled mice to run 60% to 75% longer and further than controls. When combined with exercise, results exceeded either intervention alone. AICAR alone (without exercise) enhanced running endurance by 44% in sedentary mice. Significance: This landmark study, published in Cell, established GW-501516 as the prototype “exercise mimetic” and demonstrated that the AMPK-PPARδ pathway can be pharmacologically

targeted to enhance training adaptation or increase endurance without exercise. The study prompted WADA to add GW-501516 to its banned substances list in 2009.

Study 2: Sprecher et al. – Arteriosclerosis, Thrombosis, and Vascular Biology (2007) Design: First-in-human clinical trial. Healthy volunteers received placebo (n=6) or GW-501516 at 2.5 mg (n=9) or 10 mg (n=9) orally once daily for 2 weeks while hospitalized and sedentary. Standard lipid/lipoprotein panels were measured, and in vivo fat-feeding studies were conducted. Human skeletal muscle cells were also treated with GW-501516 in vitro. Results: Serum triglycerides trended downward (P=0.08 at 10 mg), while triglyceride clearance post fat-feeding significantly improved (P=0.02). HDL cholesterol increased significantly. In vitro, GW-501516 upregulated lipid-related gene expression and fatty acid oxidation in human skeletal muscle cells, and increased apolipoprotein A1-specific cholesterol efflux. Significance: The first report of a PPAR-δ agonist administered to humans. Confirmed that GW- 501516 significantly influenced HDL and triglyceride levels in healthy volunteers and provided the first human evidence of enhanced fat utilization through PPAR-δ activation.

Study 3: Dressel et al. – Molecular Endocrinology (2003) Design: In vitro study examining GW-501516’s effects on gene expression in skeletal muscle cells, using selective PPARα, PPARβ/δ, PPARγ, and liver X receptor agonists to distinguish the functional roles of each receptor. Results: GW-501516 induced expression of genes involved in preferential lipid utilization, beta- oxidation, cholesterol efflux, and energy uncoupling in skeletal muscle cells. Treatment also increased apolipoprotein A1-specific efflux of intracellular cholesterol, identifying skeletal muscle as an important target of PPARβ/δ agonists. Significance: Established the molecular mechanisms by which GW-501516 shifts skeletal muscle metabolism toward fat oxidation and suggested therapeutic utility for hyperlipidemia, atherosclerosis, and obesity.

Study 4: Chen et al. – Scientific Reports (2015) Design: Metabolomic profiling study examining the effects of GW-501516 on running endurance in mice, measuring metabolic intermediates, enzyme levels, and muscle fiber composition. Results: GW-501516 enhanced running endurance and increased the proportion of SDH-positive (oxidative) muscle fibers in both trained and untrained mice. Increased levels of fatty acid oxidation metabolites and key enzymes were observed. GW-501516 specifically increased serum galactose and β-hydroxybutyrate independent of training status.

Significance: Provided metabolomic-level confirmation of GW-501516’s mechanism, showing enhanced fatty acid oxidation pathways and muscle fiber-type remodeling at the biochemical level.

Study 5: Ooi et al. – Journal of Clinical Endocrinology and Metabolism (2011) Design: Clinical trial evaluating GW-501516 in dyslipidemic subjects with central obesity and characteristics of metabolic syndrome. Results: GW-501516 produced significant changes in HDL cholesterol, LDL cholesterol, apolipoprotein A1, and apolipoprotein B. Fewer VLDL particles and larger LDL particles supported a transition toward less atherogenic lipoprotein profiles. Significance: Demonstrated that GW-501516 produces clinically meaningful lipid improvements in subjects with metabolic syndrome features, the population most likely to benefit from PPAR-δ activation.

Dosing Protocol

Important: GW-501516 is not FDA-approved and is not intended for human consumption. Pharmaceutical development was discontinued due to safety concerns in long-term rodent studies. The following information is derived from published clinical trials and commonly referenced research protocols. Any use should be under the supervision of a qualified healthcare provider.

Oral Administration

Protocol Dose Notes Low Dose 5–10 mg once daily Commonly referenced starting dose Standard 10–20 mg once daily Most commonly referenced dose range (clinical trials used 2.5–10 mg) Cycle Length 6–8 weeks Commonly referenced cycle duration Break 4–8 weeks off Between cycles; no established protocol

Dosing Considerations

• Oral bioavailability: GW-501516 is orally active and does not require injection. Clinical

trials used oral doses of 2.5 mg and 10 mg daily.

• Timing: Typically taken once daily in the morning. Some users dose 1 to 2 hours before

exercise for maximum metabolic effect.

• No reconstitution required: Available in capsule or liquid solution form. No mixing or

injection is needed.

• Dose-response: Clinical trials showed effects at doses as low as 2.5 mg daily. The

relationship between dose and cancer risk observed in rodents is an important consideration.

• No PCT required: Unlike SARMs and anabolic compounds, GW-501516 does not

affect testosterone production or the hypothalamic-pituitary-gonadal axis. No post-cycle therapy is needed.

Side Effects

Clinical Trial Safety Data

Human clinical trials (Sprecher et al., 2007; Ooi et al., 2011; Olson et al., 2012) reported that GW-501516 was generally well tolerated at doses of 2.5 to 10 mg daily over 2-week periods. No serious adverse events were reported in these short-term studies.

Commonly Reported (Anecdotal) Side Effect Frequency Notes Headache Occasional Usually mild and transient Nausea Uncommon Typically with initial doses Gastrointestinal discomfort Uncommon Usually mild Joint or muscle discomfort Rare Anecdotal reports only

Critical Safety Concern: Cancer Risk in Rodent Studies

The most significant safety concern with GW-501516 is that high-dose, long-term rodent studies demonstrated increased cancer development in multiple organ systems. This finding caused GlaxoSmithKline to discontinue pharmaceutical development. Key considerations:

• Dose and duration: The cancer findings occurred at doses and treatment durations

significantly exceeding those used in short-term human clinical trials. The relevance of rodent cancer findings to human risk at lower doses and shorter durations remains debated.

• Species specificity: GW-501516 appears to be a more selective PPAR-δ agonist in

humans than in rodents, which may make direct translation of rodent cancer data uncertain. However, this does not eliminate the concern.

• No long-term human data: No long-term human safety studies have been conducted.

The risk of cancer or other serious adverse effects with chronic human use is unknown.

• Ongoing research: Newer-generation PPAR-δ agonists (ASP0367, Seladelpar, REN-

001) are being developed with improved safety profiles, suggesting the pharmaceutical

industry continues to view the PPAR-δ pathway as therapeutically valuable despite the GW-501516 safety concerns.

Contraindications and Precautions

Do Not Use If You Have:

• Active cancer or history of cancer: Given the rodent cancer findings, individuals with

active malignancies or a history of cancer should absolutely not use GW-501516.

• Pregnancy or breastfeeding: No safety data exists. Effects on fetal development are

unknown.

• Liver disease: PPAR-δ is expressed in hepatic tissue, and the effects of chronic

activation on compromised liver function are unknown. Use with Caution:

• Concurrent medications: PPAR-δ activation affects lipid metabolism and gene

expression broadly. Potential interactions with lipid-lowering medications, diabetes medications, and anticoagulants should be considered.

• Long-term or chronic use: No long-term safety data exists in humans. Short research

windows with conservative dosing are strongly recommended.

• Competitive athletes: GW-501516 has been prohibited by WADA since 2009. It is

easily detectable in blood and urine testing. WADA issued an unprecedented warning to athletes about GW-501516 in 2013.

Cardarine vs. Traditional Performance Compounds

Compound Class Mechanism Primary Effect Hormonal

Impact

GW-501516 PPAR-δ Nuclear receptor Endurance, fat None (no agonist activation; gene oxidation, lipid androgen receptor transcription modulation binding) Ostarine SARM Selective androgen Lean muscle Mild testosterone (MK-2866) receptor preservation, bone suppression modulation density SR9009 Rev-Erb Circadian rhythm Endurance, None (Stenabolic) agonist regulation; metabolic rate mitochondrial activity Clenbuterol Beta-2 Sympathomimetic Thermogenesis, fat None directly; agonist stimulation loss cardiac stress Testosterone Anabolic Androgen receptor Muscle Significant (HPTA steroid activation hypertrophy, suppression) strength

Unlike anabolic agents or androgen-based compounds, Cardarine does not bind to androgen receptors, does not affect testosterone production, and does not promote muscle hypertrophy directly. Its effects are primarily metabolic, not hormonal—making it a distinct category of research compound focused on endurance and energy efficiency rather than muscle growth. No post-cycle therapy is required.

Success Tips

Pair with Exercise for Synergistic Effects

The Narkar et al. (2008) study demonstrated that GW-501516 and exercise training produce synergistic effects greater than either alone. For maximum benefit, combine Cardarine use with a structured endurance or cardiovascular training program rather than relying on the compound alone.

Maintain a Caloric Strategy

Cardarine enhances fat oxidation but does not override caloric balance. For body composition goals, maintain an appropriate caloric deficit or maintenance level. The compound’s fat- oxidation effects are most pronounced during exercise and metabolic stress.

Use Short Research Windows

Given the absence of long-term human safety data and the rodent cancer findings, responsible use involves short research windows (6–8 weeks), conservative dosing (starting at the lower end of referenced ranges), and adequate breaks between cycles.

Monitor Lipid Panels

Since GW-501516 significantly affects lipid metabolism, tracking lipid panels (HDL, LDL, triglycerides, apoA1, apoB) before, during, and after use can objectively document metabolic response.

No PCT Needed

Unlike SARMs and anabolic compounds, GW-501516 does not suppress testosterone or affect the hypothalamic-pituitary-gonadal axis. No post-cycle therapy is required.

Storage and Handling

• Capsules: Store at controlled room temperature (20–25°C / 68–77°F). Protect from light,

heat, and moisture. Keep in the original container.

• Liquid solutions: Store at room temperature or refrigerate per manufacturer’s

instructions. Protect from light. Use within the shelf life specified by the supplier.

• Stability: GW-501516 is a stable compound with a long shelf life when stored properly.

It is noted in the literature as having a long half-life, contributing to its ease of detection in doping tests.

• Keep out of reach: Store securely, away from children and pets.

Legal Status

United States: GW-501516 is not FDA-approved for any medical condition and is not classified as a controlled substance. It is available as a research chemical but cannot be legally marketed for human consumption. WADA Status: GW-501516 has been prohibited by the World Anti-Doping Agency since 2009, initially classified under gene doping and now under the S4.5 Metabolic Modulators category. It is prohibited at all times (in and out of competition). WADA issued an unprecedented warning to athletes in 2013 specifically about GW-501516, citing the cancer risk observed in animal studies. Multiple athletes, including members of the Russian race-walking team, have been suspended for testing positive for GW-501516. International: No PPAR-δ agonist has been approved for human therapy in any country. GW-501516 is generally available through research chemical suppliers in most jurisdictions. Users should verify the legal status in their specific region.

Frequently Asked Questions

Is Cardarine a SARM?

No. Although frequently grouped with SARMs in consumer marketing, Cardarine (GW-501516) is a PPAR-δ agonist. It does not bind to androgen receptors, does not affect testosterone production, and works through an entirely different biological pathway focused on metabolic gene expression rather than hormonal signaling. Will Cardarine cause cancer? High-dose, long-term rodent studies showed increased cancer development in multiple organ systems, which halted pharmaceutical development. However, these studies used doses and durations exceeding those in human clinical trials. Short-term human trials showed no cancer signals. The long-term cancer risk in humans at lower doses is unknown. This is the single most important safety consideration with GW-501516. Does Cardarine suppress testosterone? No. GW-501516 does not bind to androgen receptors and does not affect testosterone production or the hypothalamic-pituitary-gonadal axis. No post-cycle therapy is required. How quickly does Cardarine work? Metabolic effects (improved fat oxidation, enhanced endurance) may be noticed within the first 1 to 2 weeks. Lipid panel changes were documented within 2 weeks in clinical trials. Full effects develop over the course of a 6- to 8-week cycle.

Can I stack Cardarine with SARMs?

Some users combine GW-501516 with SARMs for complementary effects (endurance/fat oxidation from Cardarine, lean mass from SARMs). However, combining investigational compounds introduces unknown interaction risks. If stacking, introduce compounds individually to assess tolerance before combining. Are there safer alternatives to GW-501516? Next-generation PPAR-δ agonists (ASP0367/MA-0211, Seladelpar/MBX-8025, REN-001) are being developed with improved safety profiles. Additionally, exercise-mimicking compounds targeting related pathways (SLU-PP-332, an ERR agonist) are in early research stages. However, none of these are currently available outside of clinical trials.

References

1. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405–415. https://pubmed.ncbi.nlm.nih.gov/18674809/ 2. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator-activated receptor δ agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359–365. 3. Dressel U, Allen TL, Pippal JB, et al. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003;17(12):2477–2493. 4. Chen W, Gao R, Xie X, et al. A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015;5:9884. 5. Ooi EM, Watts GF, Sprecher DL, et al. Mechanism of action of a peroxisome proliferator- activated receptor (PPAR)-δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568–E1576. 6. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2012;61(10):2441. 7. Brunmair B, Staniek K, Dörig J, et al. Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia. 2006;49(11):2713–2722. 8. Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2004;2(10):e294. 9. Paw M, Wnuk D, Madeja Z, Michalik M. PPARδ agonist GW501516 suppresses the TGF-β- induced profibrotic response of human bronchial fibroblasts from asthmatic patients. Int J Mol Sci. 2023;24(9):7721.